Development of molecular assays based on epigenetic biomarkers which allow early and reliable cancer diagnostics – this is the intention of oncgnostics! Our products should allow an early detection of diseases to substantially inprove therapy success. Notice: if detected early, almost all cancer cases are curable.
oncgnostics develops and markets - based on proprietary epigenetic biomarkers - highly reliable, molecular biology-based in vitro diagnostic (=IVD) tests for screening, therapeutic decisions and follow-up care in cancer diagnostics. First product is GynTect, an IVD for detecting cervical (pre-) cancer cases. Pipeline projects are in the field of head and neck cancer and ovarian cancer diagnostics.